All Reports and Publications

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

All Reports and Publications

Fewer than One in Five Medicare Enrollees Received Medication to Treat Their Opioid Use Disorder

Medicare Part D Spending for 10 Selected Diabetes Drugs Totaled $35.8 Billion in 2023, an Increase of 364 Percent From 2019

Medicare Contractors Did Not Use Complete and Timely Utilization Data When Making Part B Coverage Determinations for Stelara

Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Third Quarter of 2024

Not All Medicare Enrollees Are Continuing Treatment for Opioid Use Disorder

West Virginia Did Not Always Invoice Rebates to Manufacturers for Physician-Administered Drugs

How FDA Used Its Accelerated Approval Pathway Raised Concerns in 3 of 24 Drugs Reviewed

Update: Xolair Prefilled Syringes Likely Meet Part B Coverage Criteria

Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Second Quarter of 2024

Medicare Part D Paid Millions for Drugs for Which Payment Was Available Under the Medicare Part A Skilled Nursing Facility Benefit

Medicare and Medicaid Enrollees in Many High-Need Areas May Lack Access to Medications for Opioid Use Disorder

Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2022 Average Sales Prices

South Carolina Did Not Always Invoice Rebates to Manufacturers for Physician-Administered Drugs Dispensed to Enrollees of Medicaid Managed-Care Organizations

Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the First Quarter of 2024

Medicare and Some Enrollees Paid Substantially More When Stelara Was Covered Under Part D Versus Part B

Part D Plans Generally Include Drugs Commonly Used by Dual-Eligible Enrollees: 2024

Medicaid Managed Care: States Do Not Consistently Define or Validate Paid Amount Data for Drug Claims

State Agencies Could Be Obtaining Hundreds of Millions in Additional Medicaid Rebates Associated With Physician-Administered Drugs

Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Fourth Quarter of 2023

Data Snapshot: Biosimilar Cost and Use Trends in Medicare Part B

All Reports and Publications

Filters